Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   39806   clinical trials with a EudraCT protocol, of which   6534   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2008-002151-25
    Sponsor's Protocol Code Number:D4260C00007
    National Competent Authority:Finland - Fimea
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2008-06-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFinland - Fimea
    A.2EudraCT number2008-002151-25
    A.3Full title of the trial
    A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Multi-Centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Blood and Urine of AZD1236 Administered as Oral Tablet in Moderate to Severe COPD Patients During a 6 Week Treatment Period.
    A.3.2Name or abbreviated title of the trial where available
    BICO
    A.4.1Sponsor's protocol code numberD4260C00007
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstraZeneca AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code AZD1236
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeAZD1236
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level LLT
    E.1.2Classification code 10010952
    E.1.2Term COPD
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to assess the effects of AZD1236 compared with placebo on
    selected biomarkers in induced sputum, urine and blood in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
    E.2.2Secondary objectives of the trial
    Secondary objectives are to assess the effects of AZD1236 on lung function and COPD symptoms, the safety and tolerability of AZD1236 and the systemic exposure of AZD1236. A genetic sample will be collected from patients giving separate informed consent for this.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Provision of informed consent prior to any study specific procedures
    2. Men, or postmenopausal/hysterectomised/oophorectomised women ≥ 40 years of
    age. Postmenopausal women defined as being amenorrhoeic for at least 24 months.
    3. A minimum weight of 50 kg
    4. Diagnosis of COPD for at least 1 month.
    5. FEV1 40-80% of the predicted normal value (post bronchodilator) and
    post-bronchodilator FEV1/FVC<70%
    6. Current or ex-smokers with a smoking history of at least 10 pack years (1 pack
    year = 20 cigarettes smoked per day for one year. For cigars, cigarillos etc see
    further information in the eCRF instructions)
    7. Patients that are able to discontinue all non-allowed concomitant medication
    8. Recent or current use of short acting rescue/reliever medication
    9. Be able to comply with induced sputum procedure and produce sputum.
    Randomisation inclusion criteria at Visit 3
    1. A score ≥ 1 on the breathlessness score on at least half of the numbers of days (at least 6 days with a score ≥ 1 on the breathlessness score are needed).
    E.4Principal exclusion criteria
    1. Any clinically relevant disease or disorder (past or present), which in the opinion
    of the investigator may either put the patient at risk because of participation in the
    study, or influence the results of the study, or the patient’s ability to participate
    in the study
    2. Any current respiratory tract disorders other than COPD, which are considered by
    the investigator to be clinically significant or may influence the result of the study
    3. A clinical suspicion of active or latent tuberculosis defined as any of the following:
    a) positive tuberculosis test (such as Quantiferon GOLD or Mantoux-test,
    >5 mm in unvaccinated individuals and >10 mm in individuals with previous
    BCG-vaccination),
    and/or
    b) suspicion of active or latent tuberculosis on chest X-ray taken within last 12
    months.
    and/or
    c) past medical history of tuberculosis
    4. Malignancy or neoplastic disease within the last 5 years, other than treated basal
    squamous cell skin cancer or treated cervical cancer in situ
    5. Disease history suggesting reduced or abnormal immune function
    6. Any clinically relevant abnormal finding in physical examination, clinical
    chemistry, haematology, urinalysis, vital signs or ECG at baseline, which, in
    the opinion of the investigator, may put the patient at risk because of his/her
    participation in the study
    7. Patients with glomerular filtration rate less than 60 mL/min, calculated as creatinine clearance from serum-creatinine according to the Cockcroft and Gault formula: (CLcreatinine (mL/min)=constant x (140-age) x weight (kg)/serum creatinine (µM). Constant being 1.23 for men and 1.04 for women.
    8. Known HIV infection, or patient who belong to high risk group of HIV
    9. Increased Cardiac Troponin I>Upper Limit of Normal (ULN) at Visit 2
    10. Patients with underlying musculoskeletal symptoms of unknown origin and
    patients with shoulder girdle musculoskeletal symptoms or Dupuytrens contracture
    symptoms as judged by the investigator
    11. Requirement for regular oxygen therapy
    12. An exacerbation of COPD (use of oral or parenteral antibiotics and/or oral or
    parenteral glucocorticosteroids and/or hospitalisation related to COPD) within 30
    days of Visit 2 or during run-in
    13. Use of oral or parenteral glucocorticosteroids within 30 days prior to Visit 2, or
    during the run-in period
    14. Use of inhaled glucocorticosteroids within 14 days prior to Visit 2 or during the
    run-in period
    15. Known or suspected hypersensitivity to study therapy or excipients of the
    investigational product
    16. History of, or current alcohol abuse or drug abuse, as judged by the investigator
    17. Scheduled in-patient hospitalisation during the course of the study
    18. Donation of blood within 3 months prior to Visit 2
    19. Vaccination within 2 weeks prior to Visit 2
    20. Previous randomisation of treatment in the present study
    21. Participation in another study involving drug administration within 3 months
    of Visit 2
    22. Involvement in the planning and/or conduct of the study (applies to both
    AstraZeneca staff and/or staff at the study site)
    23. Clinical judgement by the investigator that the patient should not participate in
    the study
    If the patient participates in the genetic part of the study these exclusion criteria apply as well:
    24. Whole blood transfusion within 120 days of the date of genetic sample collection
    25. Previous bone marrow transplant.
    E.5 End points
    E.5.1Primary end point(s)
    Safety
    Adverse events, blood pressure, pulse, ECG and laboratory safety variables (clinical
    chemistry, haematology, urinalysis).
    The primary variables in this study are differential cell count (both % of total cell count and absolute numbers) and TNF-α in induced sputum and 24 hour urinary desmosine excretion.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the entire study is defined as database lock since the analysis of biomarkers will take at least 6 weeks after the last visit of the last patient undergoing the trial.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 40
    F.4.2.2In the whole clinical trial 40
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2008-07-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2008-08-15
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2009-08-20
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA